Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma and Lupin Pharma Canada have signed an exclusive agreement to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada for ADHD treatment. These products will be the only orally disintegrating, extended-release tablets for ADHD in Canada once approved by Health Canada. Adzenys XR-ODT is bioequivalent to Adderall XR, while Cotempla XR-ODT is the only extended-release orally disintegrating methylphenidate tablet.

Aytu's ADHD portfolio has seen a 16.5% increase in prescriptions over the past two years. The Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales in 2023. Lupin will seek regulatory approvals for both products, expected within the next 18 to 24 months.

Aytu BioPharma reported fiscal 2024 full year and fourth quarter results. Key highlights include:

- Full year consolidated net revenue of $81.0 million, with Rx Segment revenue of $65.2 million

- ADHD Portfolio net revenue increased 23% to $57.8 million

- Adjusted EBITDA improved to $9.2 million, up $5.7 million from fiscal 2023

- Cash balance of $20.0 million as of June 30, 2024

The company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025. Aytu completed the wind down and divestiture of its Consumer Health Segment in July 2024, focusing on its higher-margin Rx Segment. The ADHD Portfolio saw strong growth, while the Pediatric Portfolio was impacted by payer changes but is showing signs of recovery.

Aytu BioPharma (Nasdaq: AYTU) has announced it will report its fiscal 2024 full year and fourth quarter operational and financial results on September 26, 2024, after market close. The company has scheduled a conference call and webcast for the same day at 4:30 p.m. Eastern time to review the results and conduct a Q&A session.

Interested parties can access the conference call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) using the participant access code 216512. The webcast will be available live and archived at a specific URL and on the Investors section of Aytu's website. A teleconference replay will be accessible until October 10, 2024.

Aytu BioPharma (Nasdaq: AYTU) has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. The company's CEO, Josh Disbrow, will deliver a webcasted presentation on Thursday, August 15, at 12:15 p.m. Eastern time. This fireside chat will be accessible through Aytu's investor relations website and will remain available for replay after the event.

In addition to the presentation, Aytu's management team will engage in one-on-one meetings with investors throughout the conference. Interested parties can arrange meetings through their Sidoti representatives or by contacting Aytu's investor relations team directly. This event provides an opportunity for investors to gain insights into Aytu BioPharma, a pharmaceutical company focused on commercializing novel therapeutics.

Aytu BioPharma (Nasdaq: AYTU) has announced the sale of its Consumer Health business following a strategic wind down of operations. The divestiture includes the e-commerce platform, inventory, consumer brands, intellectual property, contracts, and liabilities. Aytu will receive revenue-based royalty payments on future sales of former Consumer Health products.

The move aligns with Aytu's strategy to focus on its prescription pharmaceutical business and achieve consistent profitability. The company expects this strategic shift, along with the closure of its Grand Prairie, Texas manufacturing site, to significantly enhance operating results and drive stockholder value. The Consumer Health business had been operating at near adjusted EBITDA breakeven during the wind down period.

Aytu BioPharma has refinanced its existing term loan and extended its revolving credit facility on more favorable terms. The company received $3.5 million by exercising warrants and used part of this to reduce its term loan debt. The new $13 million term loan has a lower interest rate of 12.4%, down from 15.9%, potentially saving $1.3 million in interest payments. The term loan's maturity date is extended to June 12, 2028. Additionally, the revolving credit facility's borrowing capacity has increased. These moves are part of Aytu's strategic focus on enhancing financial stability and growth.

The company reclassified most of its term loan from current to long-term liabilities, improving financial ratios. The warrant exercise resulted in 2,173,912 common shares being converted to 367,478 common shares and 1,806,434 pre-funded warrants. As of June 18, 2024, Aytu has 5,972,327 common shares outstanding.

Aytu BioPharma will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, led by CEO Josh Disbrow, plans to host a webcasted fireside chat at 1:15pm ET and engage in one-on-one investor meetings. The event will be held virtually, and interested parties can access the webcast via the conference home page or directly through a provided link. The webcast will also be available for replay. To schedule a one-on-one meeting, investors should contact Lytham Partners or register on the event's website.

Aytu BioPharma, Inc. (NASDAQ:AYTU) will report its third-quarter fiscal 2024 financial and operational results on May 15, 2024. A conference call and webcast are scheduled for the same day at 4:30 p.m. Eastern Time to review the results.